We are live on
!
Find out more
AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
This Fund
S&P 500
This Quarter
Est. Return
+5.45%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$180M
AUM Growth
+$35.3M
(+24%)
Cap. Flow
+$33.3M
Cap. Flow
% of AUM
18.49%
Top 10 Holdings %
Top 10 Hldgs %
21.58%
Holding
287
New
78
Increased
46
Reduced
73
Closed
55
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Jazz Pharmaceuticals
JAZZ
|
+$4.54M |
| 2 |
Coherus Oncology
CHRS
|
+$3.29M |
| 3 |
Amylyx Pharmaceuticals
AMLX
|
+$2.71M |
| 4 |
Embecta
EMBC
|
+$2.55M |
| 5 |
Invesco S&P 500 Pure Value ETF
RPV
|
+$2.33M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 1-3 Year Treasury Bond ETF
SHY
|
+$4.1M |
| 2 |
Invesco QQQ Trust
QQQ
|
+$2.81M |
| 3 |
Invesco NASDAQ 100 ETF
QQQM
|
+$2.81M |
| 4 |
Innoviva
INVA
|
+$2.07M |
| 5 |
Bio-Rad Laboratories Class A
BIO
|
+$1.63M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 59.9% |
| 2 | Real Estate | 10.66% |
| 3 | Financials | 4.01% |
| 4 | Technology | 3.46% |
| 5 | Consumer Discretionary | 2.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Jazz Pharmaceuticals
JAZZ
$15.2B
| $5.05M | 2.8% |
40,750
+33,750
| +482% | +$4.54M |
|
2
Rithm Capital
RITM
$5.26B
| $4.6M | 2.55% |
491,699
| – | – |
|
3
Harmony Biosciences
HRMY
$1.94B
| $4.15M | 2.3% |
118,000
+50,500
| +75% | +$1.74M |
|
|
LKFT
4
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.94B
| $4.03M | 2.23% |
99,000
+7,000
| +8% | +$286K |
|
5
BioCryst Pharmaceuticals
BCRX
$2.31B
| $4.01M | 2.23% |
570,000
+150,500
| +36% | +$1.21M |
|
|
6
Coherus Oncology
CHRS
$214M
| $3.9M | 2.16% |
912,500
+558,000
| +157% | +$3.29M |
|
7
Neurocrine Biosciences
NBIX
$17.2B
| $3.44M | 1.91% |
36,500
+21,000
| +135% | +$2.05M |
|
8
AdaptHealth
AHCO
$1.48B
| $3.44M | 1.91% |
282,500
+166,000
| +142% | +$1.85M |
|
|
EFC
9
Ellington Financial
EFC
$1.72B
| $3.3M | 1.83% |
239,271
+39,100
| +20% | +$498K |
|
10
Elanco Animal Health
ELAN
$13B
| $2.97M | 1.65% |
295,000
+80,000
| +37% | +$742K |
|
11
Arcutis Biotherapeutics
ARQT
$3.47B
| $2.79M | 1.55% |
292,500
+102,500
| +54% | +$1.14M |
|
12
Centene
CNC
$31.5B
| $2.7M | 1.5% |
40,000
-10,000
| -20% | -$667K |
|
|
HZNP
13
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $2.62M | 1.46% |
25,500
| – | – |
|
|
14
Invesco S&P 500 Pure Value ETF
RPV
$1.58B
| $2.42M | 1.34% |
+31,211
| New | +$2.33M |
|
15
iShares Russell 1000 Value ETF
IWD
$81.9B
| $2.37M | 1.31% |
+15,005
| New | +$2.29M |
|
|
16
Amylyx Pharmaceuticals
AMLX
$1.89B
| $2.33M | 1.29% |
108,000
+100,500
| +1,340% | +$2.71M |
|
|
WBA
17
DELISTED
Walgreens Boots Alliance
WBA
| $2.28M | 1.26% |
80,000
+52,000
| +186% | +$1.69M |
|
18
Pacira BioSciences
PCRX
$1.01B
| $2.26M | 1.26% |
56,500
+20,500
| +57% | +$848K |
|
|
19
iShares 1-3 Year Treasury Bond ETF
SHY
$25.7B
| $2.17M | 1.21% |
26,793
-50,199
| -65% | -$4.1M |
|
|
MFA
20
MFA Financial
MFA
$977M
| $2.11M | 1.17% |
187,725
+14,300
| +8% | +$152K |
|
|
COOP
21
DELISTED
Mr. Cooper
COOP
| $2.09M | 1.16% |
41,290
-15,500
| -27% | -$710K |
|
22
iShares MBS ETF
MBB
$39.3B
| $2.05M | 1.14% |
+21,955
| New | +$2.06M |
|
|
23
Embecta
EMBC
$199M
| $2.02M | 1.12% |
+93,500
| New | +$2.55M |
|
24
Insmed
INSM
$23.3B
| $2M | 1.11% |
95,000
+10,500
| +12% | +$199K |
|
25
United Therapeutics
UTHR
$22.5B
| $1.99M | 1.1% |
9,000
+5,500
| +157% | +$1.22M |
|
Similar funds
WCM
FCM
BIA
AGAM
E
HCM
AC
OIS
AlphaCentric Advisors's Q2 2023 Portfolio in Review
As of Q2 2023, AlphaCentric Advisors held 287 positions worth $180M, up 24% from $145M the previous quarter. Its ten largest holdings account for 22% of the portfolio.
AlphaCentric Advisors deployed $33.3M of net new capital in Q2 2023, opening 78 new positions and adding to 46 existing holdings. Its largest new stake was Embecta: 93,500 shares worth $2.02M.
By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 56% a quarter earlier, followed by Real Estate and Financials.
On the sell side, the largest reduction was iShares 1-3 Year Treasury Bond ETF, an estimated $4.1M trimmed.
- AlphaCentric Advisors's largest Q2 2023 buy was Embecta: 93,500 shares worth $2.02M.
- AlphaCentric Advisors added most to Jazz Pharmaceuticals in Q2 2023, an estimated $4.54M increase.
- AlphaCentric Advisors's biggest Q2 2023 reduction was iShares 1-3 Year Treasury Bond ETF, cutting an estimated $4.1M.
- AlphaCentric Advisors fully exited Invesco QQQ Trust in Q2 2023, selling an estimated $2.81M.
- AlphaCentric Advisors's ten largest holdings make up 22% of its $180M portfolio in Q2 2023.
- AlphaCentric Advisors opened 78 new positions and closed 55 in Q2 2023.
- AlphaCentric Advisors's portfolio value rose 24% quarter-over-quarter to $180M.
Based on AlphaCentric Advisors's 13F filing for Q2 2023, filed 8 Aug 2023.